Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Cartilage Repair Histogenics Resets The Stage

This article was originally published in Start Up

Executive Summary

In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.

You may also be interested in...



Failed Phase III For NeoCart May Still Fly With US FDA, Histogenics Argues

Agency guidance does not require coprimary, dual responder endpoint for drugs developed for knee cartilage repair, so in Histogenics' view, door is still open for approval.

Progress In Cartilage Repair: The Holy Grail Of Knee OA

Researchers have been working for years to develop a reliable and cost-effective means of regenerating the hyaline cartilage found in the knee, with the aim of offering a minimally invasive treatment option for the millions of patients with painful knee osteoarthritis. Although this goal has been elusive so far, recent progress suggests the field may have turned a corner, and a large number of companies are now competing to win this quest, which many refer to as the “Holy Grail” of knee OA.

Medtech’s Share Of Private Investment Dollars In 2012

Each year, START-UP reviews the sectors of the medical device industry that received private funding to see what will be filling the pipelines of medical device companies in the future. Despite gloomy talk by VCs and strategics predicting a future scarcity of new innovative products, the actual data from 2012 show many categories holding steady and pockets of up-and-coming technologies attracting investment.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel